Frontiers in Pharmacology | Pharmacogenetics and Pharmacogenomics

Original Research

Accepted on 09 Oct 2025

Effectiveness of Treatments to Prevent Femoral Periprosthetic Bone Loss in People Following Total Hip Arthroplasty: A Network Meta-analysis

in Pharmacogenetics and Pharmacogenomics

Zhihu Zhao
Tao Ling
Zhihu Zhao
Wei Luo
Jian-Xiong Ma
Xinlong Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1566890

Original Research

Published on 09 Oct 2025

Patient and clinician perspectives on pharmacogenetic testing for antipsychotics

in Pharmacogenetics and Pharmacogenomics

Maria Richards-Brown
Yiran Wei
Rosemary Abidoph
Lauren Varney
Marius Cotic
Stephen Murtough
Daniele Panconesi
Daisy Mills
Alvin Richards-Belle
Noushin Saadullah Khani

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1689300

1,463 views

Original Research

Published on 08 Oct 2025

A digital twin of glimepiride for personalized and stratified diabetes treatment

in Pharmacogenetics and Pharmacogenomics

Michelle Elias
Matthias König

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1686415

734 views

Original Research

Published on 02 Oct 2025

Genetic and serum biomarkers of NSAID hypersensitivity reactions

in Pharmacogenetics and Pharmacogenomics

G. Amo
J. M. García-Menaya
M. Martí
J. Gómez-Tabales
J. A. Cornejo-García
N. Blanca-López
G. Canto
I. Doña
M. Blanca
M. J. Torres

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1502755

1,477 views

Review

Published on 01 Oct 2025

Pharmacogenomics of antibiotic-induced hypersensitivity reactions: current evidence and implications in clinical practice

in Pharmacogenetics and Pharmacogenomics

Mohitosh Biswas
Murshadul Alam Murad
Md. Ismail Hossain Ashik
Maliheh Ershadian
Chonlaphat Sukasem

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1651909

1,565 views

Original Research

Accepted on 29 Sep 2025

Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder

in Pharmacogenetics and Pharmacogenomics

Daniel Hain
Andria L Del Tredici
Ryan B Griggs
Rebecca Law
Brent Mabey
Holly L Johnson
Katie Johansen Taber
Kevin G Lynch
Alexander Gutin
David W Oslin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1658616

413 views

Original Research

Published on 25 Sep 2025

Pharmacogenomic biomarkers of ACE inhibitor–induced cough in a multi-ethnic UAE cohort

in Pharmacogenetics and Pharmacogenomics

Sahar M. Altoum
Zeina N. Al-Mahayri
Lubna Q. Khasawneh
Mais N. Alqasrawi
Lilas Dabaghie
Dana Hamza
Bassam R. Ali

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1655617

1,389 views

Systematic Review

Published on 22 Sep 2025

Implementing pharmacogenetic testing in community pharmacy practice: a scoping review

in Pharmacogenetics and Pharmacogenomics

Aude Coumau
Claire Coumau
Chantal Csajka

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1659875

2,370 views

Review

Published on 19 Sep 2025

Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions

in Pharmacogenetics and Pharmacogenomics

Hamid A. Alhaj
Jana Samara
Alyamama Alnamous
Rama Karima
Maha Saber-Ayad

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1651898

2,542 views

Original Research

Published on 19 Sep 2025

Prevalence of risk phenotypes associated with CYP2C92, 3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice

in Pharmacogenetics and Pharmacogenomics

Mohitosh Biswas
Murshadul Alam Murad
Maliheh Ershadian
Most. Sumaiya Khatun Kali
Maw Shin Sim
Baharudin Ibrahim
Chonlaphat Sukasem

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1597379

1,186 views
1 citation

Original Research

Published on 18 Sep 2025

Higher prevalence of NUDT15 rs116855232 compared to TPMT rs1142345 in a Chinese cohort and its implications for thiopurine therapy

in Pharmacogenetics and Pharmacogenomics

Chenyu Zhao
Hui Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1660719

1,308 views

Original Research

Published on 18 Sep 2025

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger

in Pharmacogenetics and Pharmacogenomics

Rocío Rosas-Alonso
Nuria Rodríguez Salas
Pablo Perez Wert
Angela Hoyo
Susana Martin-López
Daniel Martínez-Pérez
Iciar Ruiz-Gutiérrez
Diego Jiménez-Bou
Jesús Peña
Pedro Arias

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1645188

1,418 views

Brief Research Report

Published on 09 Sep 2025

Comparative evaluation of Oxford Nanopore Technologies’ adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling

in Pharmacogenetics and Pharmacogenomics

Koen Deserranno
Laurentijn Tilleman
Dieter Deforce
Filip Van Nieuwerburgh

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1653999

1,768 views

Review

Published on 04 Sep 2025

Epigenetics in pharmacogenes encoding metabolizing enzymes of second-generation antipsychotics used in schizophrenia and its clinical implications

in Pharmacogenetics and Pharmacogenomics

Angel T. Alvarado
Amparo Iris Zavaleta
César Li-Amenero
María R. Bendezú
Jorge A. Garcia
Haydee Chávez
Juan J. Palomino-Jhong
Felipe Surco-Laos
Doris Laos-Anchante
Elizabeth J. Melgar-Merino

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1611203

2,307 views

Original Research

Published on 01 Sep 2025

The prevalence of genetic variants of the Mas-related G-protein-coupled receptor X2 in patients does not explain perioperative hypersensitivity reactions to neuromuscular blocking agents

in Pharmacogenetics and Pharmacogenomics

Alicja Dziadowiec
Mateusz Kwitniewski
Peter Kopac
Hubert Rybka
Lenka Sedlackova
Adriana Srotova
Wojciech Dyga
Ana Koren
Joanna Gluck
Radoslaw Kitel

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1655722

1,607 views

Original Research

Published on 29 Aug 2025

A multi-centre observational cohort study on pharmacogenomic predictors of rosuvastatin discontinuation in a multiethnic population

in Pharmacogenetics and Pharmacogenomics

Mais N. Alqasrawi
Zeina N. Al-Mahayri
Lubna Q. Khasawneh
Areej S. AlBawa’neh
Lilas Dabaghie
Sahar M. Altoum
Dana Hamza
Salahdein Aburuz
Virendra Misra
Gohar Jamil

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1656520

1,603 views

Effectiveness of Treatments to Prevent Femoral Periprosthetic Bone Loss in People Following Total Hip Arthroplasty: A Network Meta-analysis

Patient and clinician perspectives on pharmacogenetic testing for antipsychotics

A digital twin of glimepiride for personalized and stratified diabetes treatment

Genetic and serum biomarkers of NSAID hypersensitivity reactions

Pharmacogenomics of antibiotic-induced hypersensitivity reactions: current evidence and implications in clinical practice

Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder

Pharmacogenomic biomarkers of ACE inhibitor–induced cough in a multi-ethnic UAE cohort

Implementing pharmacogenetic testing in community pharmacy practice: a scoping review

Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions

Prevalence of risk phenotypes associated with CYP2C9*2, *3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice

Higher prevalence of NUDT15 rs116855232 compared to TPMT rs1142345 in a Chinese cohort and its implications for thiopurine therapy

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger

Comparative evaluation of Oxford Nanopore Technologies’ adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling

Epigenetics in pharmacogenes encoding metabolizing enzymes of second-generation antipsychotics used in schizophrenia and its clinical implications

The prevalence of genetic variants of the Mas-related G-protein-coupled receptor X2 in patients does not explain perioperative hypersensitivity reactions to neuromuscular blocking agents

A multi-centre observational cohort study on pharmacogenomic predictors of rosuvastatin discontinuation in a multiethnic population

Prevalence of risk phenotypes associated with CYP2C92, 3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice